Form 4: BridgeBio Pharma Director Receives Significant Equity Grants

BridgeBio Pharma, Inc. Director Randal W. Scott was granted 6,589 restricted stock units and 8,425 stock options, aligning his interests with shareholders.

Summary

• Randal W. Scott, a Director of BridgeBio Pharma, Inc. (BBIO), reported the acquisition of equity securities.
• On June 20, 2025, Mr. Scott was granted 6,589 Restricted Stock Units (RSUs) under the Issuer's 2021 Amended and Restated Stock Option and Incentive Plan.
• Each RSU represents a contingent right to receive one share of BridgeBio Pharma's Common Stock.
• These RSUs will vest in three equal annual installments, with one-third vesting each year after June 20, 2025, leading to full vesting on June 20, 2028, contingent on Mr. Scott's continued service on the board.
• Additionally, on June 20, 2025, Mr. Scott was granted 8,425 stock options with an exercise price of $41.73 per share.
• Similar to the RSUs, these stock options will vest in three equal annual installments, with one-third vesting each year after June 20, 2025, and full vesting by June 20, 2028, subject to continued board service.
• The stock options have an expiration date of June 19, 2035.
• Following these transactions, Mr. Scott directly beneficially owns 11,589 shares of Common Stock and 8,425 stock options.
• He also indirectly beneficially owns 4,000 shares of Common Stock through Thinking Bench Capital LLC.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the equity grants align the director's interests with shareholders, which is generally viewed favorably. However, as a routine compensation event, it does not significantly alter the company's fundamental outlook.

Positives

• The grant of restricted stock units and stock options to Director Randal W. Scott aligns his financial interests directly with the long-term performance and shareholder value of BridgeBio Pharma, Inc.
• Equity compensation is a standard practice for retaining and incentivizing key board members, demonstrating the company's commitment to its governance structure.

Future Outlook

The future outlook for these equity grants is tied to the vesting schedule, which requires the Director's continued service on the board until June 20, 2028, for full vesting of both RSUs and stock options. The stock options have a long-term expiration date of June 19, 2035, providing a significant window for potential exercise.

Industry Context

This SEC Form 4 filing reflects a routine equity compensation event for a director of a publicly traded biotechnology company. Granting RSUs and stock options is a common industry practice to attract, retain, and incentivize board members, aligning their interests with long-term shareholder value creation. This type of compensation is a standard component of corporate governance and executive remuneration strategies across the pharmaceutical and biotech sectors.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants are designed to align the director's interests with those of the shareholders, potentially leading to more shareholder-centric decision-making and long-term value creation.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's broader approach to incentivizing key personnel.

Next Steps

• Continued service of Randal W. Scott on the BridgeBio Pharma, Inc. board of directors to ensure full vesting of the granted RSUs and stock options by June 20, 2028.

Key Dates

Keywords

BridgeBio Pharma, BBIO, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Vesting Schedule, Corporate Governance